This design confirms the key aspect mentioned above and underscores a perspective on clinical applicability: In cancer patients expressing either tumor neoantigens or cancer-testis antigens, the administration of long peptide vaccination elicits advantageous immune responses, contingent upon the inclusion of their MHC high-affinity epitope within the long peptide, irrespective of its provenance from the original protein. This evidence concerns the gene HLA-C and cancer.